HY Forensic Analysis

Executive Summary

Thesis: SHORT HYSTER-YALE (HY). The company is currently a falling knife in a cyclical downturn, exacerbated by severe tariff headwinds and evaporating operational leverage. While the stock trades at ~$34, the fundamentals have deteriorated violently: YTD EPS has swung from $7.57 profit in 2024 to a $(0.43) loss in 2025. With a backlog that has collapsed by $1B year-over-year and management guiding for continued losses in Q4, the current valuation prices in a V-shaped recovery that macro conditions do not support.

Key Metrics (Q3 2025):

• •Revenue: $979.1M (-3.6% YoY)
• •Operating Profit: $2.3M (-93.1% YoY)
• •Net Income: $(2.3)M (vs. $17.2M profit in Q3 '24)
• •Backlog: $1.35B (Down from $2.3B YoY)
• •Tariff Impact: ~$40M negative impact in Q3 alone

Data Freshness: Analysis based on Q3 10-Q filed Nov 2025 and market data as of Dec 07, 2025.

---

Recent Material Events (8-K Analysis)

• •Nov 04, 2025 (Earnings Release): Confirmed the catastrophic deterioration in profitability. The company reported a swing to net loss driven by lower unit volumes and massive tariff costs.
• •Strategic Realignment (Nuvera): Earlier in 2025, HY merged Nuvera into HYMH to cut costs, resulting in $16.9M in YTD restructuring/impairment charges. This signals a retreat from previous growth narratives to survival mode.
• •Acquisition (May 2025): Bolzoni acquired a small Italian manufacturer for $2.6M. Immaterial to results but distraction risk remains.

Insider Trading Activity

• •Activity Cluster (Oct 02, 2025): Multiple Form 4 filings occurred post-quarter end.
• •Signal: ⚠️ Neutral/Bearish. In the face of a 90%+ drop in operating profit and a collapsing share price, the lack of aggressive open-market buying by insiders is a loud silence. Management is not stepping in to defend the stock at these levels, suggesting they see further downside or lack visibility on the turnaround.

Current News & Market Context

• •Tariff Wars: The company is in the crosshairs of global trade tensions. Q3 results were hit by $40M in tariff costs. While management notes potential for tariff relief (Section 301 exemptions) in late 2025, the immediate impact is margin destruction.
• •Cyclical Downturn: The global lift truck market is contracting. Customers are deferring CAPEX due to economic uncertainty, leading to the backlog draining faster than it can be replenished.

---

Business Model Analysis

Revenue Mix

• •Lift Truck (Americas): The core engine is sputtering. Revenue fell 5.0% to $732.7M. Operating profit here collapsed 48.4%.
• •EMEA: A disaster zone. Swung to an operating loss of $(16.9)M from a loss of $(9.6)M prior year.
• •Bolzoni (Attachments): Revenue down 10.9%; Operating profit down 66.1%.

Pricing Power

• •⚠️ Eroding. While HY attempted pricing actions to offset costs, the volume decline (-78.3M impact) far outweighed price benefits (+7.4M). They are losing the battle against negative operating leverage.

Financial Health

Balance Sheet:

• •Cash: $71.1M (Down from $96.6M at Dec '24)
• •Total Debt: $467.8M (Up from $440.7M)
• •Leverage: Net debt is rising while EBITDA is crashing. This is a dangerous combination for a cyclical industrial.

---

Valuation Analysis

Current Price: $33.82

Reverse DCF (Implied Expectations)

To justify $33.82, the market is pricing in:

• •Implied FCF: ~$55M/year stabilized.
• •Reality: YTD Operating Cash Flow is only $29.6M and CAPEX is $38.9M. Free Cash Flow is NEGATIVE.
• •Conclusion: The stock is priced for a recovery to 2024 peak earnings ($7.57 EPS). Given the backlog collapse, this is highly unlikely in the next 12-18 months.

Comparables

• •Trailing P/E: N/A (Negative earnings in recent quarters).
• •Forward P/E: Likely >30x based on depressed 2026 estimates.

Competitive Position

• •Market Share: Under pressure from low-cost foreign competitors (mentioned in 10-Q).
• •Differentiation: Nuvera (hydrogen) was supposed to be the edge, but it's now a cost center being restructured.

Management Quality

• •Credibility: ⚠️ Management failed to adequately hedge or prepare for the tariff impact ($60M YTD hit).
• •Capital Allocation: Continued dividends ($20.2M YTD) while burning cash and increasing debt is questionable governance during a profitability crisis.

---

Risk Factors

1. •Tariff Relief (High Impact): Management noted potential reduction in Chinese tariffs could benefit Q4 by $2-3M. If broad exemptions occur, margins could snap back.
2. •Macro Pivot: A sudden drop in interest rates could reignite CAPEX spending and lift truck demand.
3. •Short Squeeze: Low float and high short interest in a small-cap can lead to volatility.

Forensic Accounting Flags

• •⚠️ Inventory Bloat: Inventory ($740M) is extremely high relative to annualized sales run-rate, leading to impairments ($4.6M YTD).
• •⚠️ Receivables: Down, but largely due to shrinking sales volume.
• •🔴 Earnings Quality: Net Income is propped up by tax benefits ($2.9M benefit in Q3). Pre-tax income was a loss of $(4.6)M.

Short Thesis

The "Cyclical Trap": HY is trading on trailing memories of 2024 profitability while facing a 2025/26 reality of losses and cash burn.

1. •Backlog Cliff: The $1B drop in backlog ensures revenue will remain suppressed well into 2026.
2. •Margin Compression: Fixed cost absorption is failing as volumes drop. Tariffs are the nail in the coffin.
3. •Q4 Guide: Management explicitly guided for a "moderate operating loss" in Q4. The bad news isn't over.

Catalysts & Timeline

• •Q4 Earnings (Feb 2026): Expected loss will confirm the broken thesis.
• •Backlog Updates: Further erosion below $1.3B will signal a prolonged recession in the business.
• •Debt Covenants: If EBITDA remains near zero, covenant tightness could force dividend suspension.

Price Targets

Investment Recommendation

RATING: SHORT Conviction: 8/10

HY is a classic short in the industrial cycle. They over-earned in 2024 and are now under-earning, but the stock price has not fully capitulated to the new reality of negative EPS and cash burn. Short into any tariff-relief news rallies.

One-Liner Thesis: With backlog collapsing by $1B and margins obliterated by tariffs, HY is priced for a recovery that isn't coming, making it a prime short candidate at $34.**